Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Tsunoda

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Plos One|January 14, 2014
Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2)Sachiko Yoshimura, Takuya Tsunoda, Ryuji Osawa, et al.
Frontiers in Immunology|June 1, 2026
Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAPFeifei Wei, Yoshiro Nakahara, Junya Isobe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancersKatsunori Imai, Shinya Hirata, Atsushi Irie, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2021
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failureAyako Tsuboya, Yutaro Kubota, Hiroo Ishida, et al.
Frontiers in Oncology|July 27, 2023
Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primaryRisako Suzuki, Kazuyuki Hamada, Ryotaro Ohkuma, et al.
Cancer Science|July 22, 2014
Guidance for peptide vaccines for the treatment of cancerYoshiyuki Yamaguchi, Hiroki Yamaue, Takuji Okusaka, et al.
Journal of Translational Medicine|April 9, 2014
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patientsHisae Iinuma, Ryoji Fukushima, Tsuyoshi Inaba, et al.
Cancer Science|January 15, 2011
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cellsYusuke Tomita, Katsunori Imai, Satoru Senju, et al.
International Journal of Cancer|January 12, 2010
Identification of SPARC as a candidate target antigen for immunotherapy of various cancersMitsuhiro Inoue, Satoru Senju, Shinya Hirata, et al.
Cancer Chemotherapy and Pharmacology|May 28, 2020
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patientsNatsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Plos One|January 14, 2014
Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2)Sachiko Yoshimura, Takuya Tsunoda, Ryuji Osawa, et al.
Frontiers in Immunology|June 1, 2026
Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAPFeifei Wei, Yoshiro Nakahara, Junya Isobe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancersKatsunori Imai, Shinya Hirata, Atsushi Irie, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2021
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failureAyako Tsuboya, Yutaro Kubota, Hiroo Ishida, et al.
Frontiers in Oncology|July 27, 2023
Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primaryRisako Suzuki, Kazuyuki Hamada, Ryotaro Ohkuma, et al.
Cancer Science|July 22, 2014
Guidance for peptide vaccines for the treatment of cancerYoshiyuki Yamaguchi, Hiroki Yamaue, Takuji Okusaka, et al.
Journal of Translational Medicine|April 9, 2014
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patientsHisae Iinuma, Ryoji Fukushima, Tsuyoshi Inaba, et al.
Cancer Science|January 15, 2011
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cellsYusuke Tomita, Katsunori Imai, Satoru Senju, et al.
International Journal of Cancer|January 12, 2010
Identification of SPARC as a candidate target antigen for immunotherapy of various cancersMitsuhiro Inoue, Satoru Senju, Shinya Hirata, et al.
Cancer Chemotherapy and Pharmacology|May 28, 2020
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patientsNatsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, et al.
Pageof 13